Antiangiogenic agents are compounds which prevent angiogenesis in vitro and/or in vivo. Angiogenesis inhibitors may be endogenous or synthetic; others are obtained from diet, for example resveratrol.

Literature (1)

Antiangiogenic Inhibitors

Cat. No. Product Name / Activity
6305 Lenalidomide
Angiogenesis inhibitor; also TNF-α inhibitor and cereblon binder
6302 Pomalidomide
Antiangiogenic; also TNF-α inhibitor and cereblon ubiquitination inhibitor
6187 SK 216
Angiogenesis inhibitor; Also PAI-1 inhibitor
6498 TASP 0277308
Potent and selective S1P1 receptor antagonist; inhibits angiogenesis


Cat. No. Product Name / Activity
5121 3PO
PFKFB3 inhibitor; antiangiogenic
5617 AZD 1480
Potent and selective JAK2 inhibitor; antiangiogenic
5029 CHC
Monocarboxylic acid transport (MCT) inhibitor; displays anti-angiogenic activities
1629 Herbimycin A
Antiangiogenic. Inhibits Src family kinases and Hsp90
5981 Itraconazole
SMO antagonist; antiangiogenic
5260 KG 5
Antiangiogenic; PDGFRβ, B-Raf, c-Raf, FLT3 and KIT inhibitor
4664 Obtustatin
Potent and selective α1β1 inhibitor; antiangiogenic
2710 OGT 2115
Antiangiogenic. Heparanase inhibitor
2954 PX 12
Thioredoxin-1 inhibitor; attenuates expression of HIF-1α
1418 Resveratrol
Cyclooxygenase inhbitor
0652 Thalidomide
Antiangiogenic; also inhibits TNF-α synthesis
1098 Tranilast

Literature for Antiangiogenics

Tocris offers the following scientific literature for Antiangiogenics to showcase our products. We invite you to request* your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.

Angiogenesis in Cancer Poster

Angiogenesis in Cancer Poster

This poster summarizes the pathogenesis of angiogenesis in cancer, as well as some of the main angiogenesis therapeutic targets.